Yu Tong Tam
Research Subjects
Yu Tong Tam has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Glen S. Kwon
Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin, 777 Highland Avenue, Madison, WI 53705, United States
5 shared publications Alavattam Sreedhara
Pharmaceutical Development, Genentech Inc., South San Francisco, CA 94080, United States
2 shared publicationsDae Hwan Shin
Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, WI 53705-2222, USA
2 shared publicationsAadithya Kannan
Pharmaceutical Development, Genentech Inc
1 shared publication- Albert Hee Lum Chow
School of Pharmacy, The Chinese University of Hong Kong, Sha Tin, Hong Kong
1 shared publication Alexander Dimmling
Pharmaceutical Development, Genentech Inc., South San Francisco, CA 94080, United States
1 shared publication
Latest Publications
- Open Access
- 4 May 2026
- Published by Springer Nature in AAPS Open
- Vol. 12  (1)
A perspective on high-concentration spray-dried monoclonal antibody suspensions for subcutaneous delivery
There is a growing demand in the subcutaneous delivery of monoclonal antibodies (mAbs) to reduce treatment burden for both patients and healthcare systems when compared to intravenous administration. However, it poses significant challenges in formulation development primarily due to high viscosities in highly concentrated solutions of mAbs for subcutaneous injection, which impacts injectability and effective dosing. Advances in protein spray drying have enabled the production of solid protein powders with enhanced stability. When suspended in non-aqueous media, these spray-dried powders facilitate the achievement of protein concentrations far exceeding 200 mg/mL to overcome challenges associated with high-concentration formulations for biologics such as solubility, viscosity, and aggregation. This perspective aims to discuss recent studies showcasing the successful application of spray-dried proteins to achieve high protein concentrations; key formulation aspects of protein spray drying with respect to subvisible particles; formulation considerations for spray-dried protein suspensions in non-aqueous media; technical and regulatory challenges for subcutaneous delivery of non-aqueous suspensions for mAbs; their knowledge gaps in clinical translation; and the need for patient-centric studies to enhance patient experience, providing insights into how future research can better balance quality and compliance. Finally, with the growing exploration of drying technologies, this article discusses the future outlook for high-concentration suspensions of therapeutic proteins.
- 4 May 2026
- Published by Springer Nature in AAPS Open
- Vol. 12  (1)
Open AccessA perspective on high-concentration spray-dried monoclonal antibody suspensions for subcutaneous delivery
There is a growing demand in the subcutaneous delivery of monoclonal antibodies (mAbs) to reduce treatment burden for both patients and healthcare systems when compared to intravenous administration. However, it poses significant challenges in formulation development primarily due to high viscosities in highly concentrated solutions of mAbs for subcutaneous injection, which impacts injectability and effective dosing. Advances in protein spray drying have enabled the production of solid protein powders with enhanced stability. When suspended in non-aqueous media, these spray-dried powders facilitate the achievement of protein concentrations far exceeding 200 mg/mL to overcome challenges associated with high-concentration formulations for biologics such as solubility, viscosity, and aggregation. This perspective aims to discuss recent studies showcasing the successful application of spray-dried proteins to achieve high protein concentrations; key formulation aspects of protein spray drying with respect to subvisible particles; formulation considerations for spray-dried protein suspensions in non-aqueous media; technical and regulatory challenges for subcutaneous delivery of non-aqueous suspensions for mAbs; their knowledge gaps in clinical translation; and the need for patient-centric studies to enhance patient experience, providing insights into how future research can better balance quality and compliance. Finally, with the growing exploration of drying technologies, this article discusses the future outlook for high-concentration suspensions of therapeutic proteins.
- 15 January 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115  (3) , 104167
Long-acting delivery of a model monoclonal antibody from ethylene vinyl acetate implants at a high loading: Drug release and protein stability
- 15 January 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115  (3) , 104167
Long-acting delivery of a model monoclonal antibody from ethylene vinyl acetate implants at a high loading: Drug release and protein stability
- 9 October 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23  (5) , 2815-2816
Voices in Molecular Pharmaceutics : Meet Dr. Yu Tong Tam, Who Explores Drug Delivery Technologies for Next Generation Biotherapeutics
- 9 October 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23  (5) , 2815-2816
Voices in Molecular Pharmaceutics : Meet Dr. Yu Tong Tam, Who Explores Drug Delivery Technologies for Next Generation Biotherapeutics
- 10 July 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22  (8) , 4983-4994
Combination of Hydroxypropyl-Beta-Cyclodextrin and Trehalose for Improved Stability of Spray-Dried Monoclonal Antibodies
Developing a stabilized spray-dried formulation for proteins is one key approach to extending the stability of a dehydrated drug product and providing a broad range of different drug delivery applications. Trehalose has been extensively studied as an excipient to preserve the protein stability in spray-dried formulations. However, the hygroscopic nature of amorphous trehalose makes it prone to recrystallization upon exposure to high temperature and humidity conditions, which can be detrimental to protein stability in the solid state. Herein, we report a formulation approach with the use of 2-hydroxypropyl-β-cyclodextrin (HPβCD) in combination with trehalose to enhance the physical stability of spray-dried solids by inhibiting or delaying the recrystallization of trehalose. Specifically, the effect of HPβCD and trehalose as an excipient alone or the combination of both excipients in stabilizing a model therapeutic monoclonal antibody (mAb1) in a spray-dried formulation has been evaluated at 25 °C/60% relative humidity (RH) and 40 °C/75% RH over 4 weeks. In the solid state, HPβCD can inhibit trehalose recrystallization of spray-dried solids exposed to stress conditions of higher temperatures and humidity. The recrystallization tendency of trehalose was found to be dependent on the protein-to-excipient mass ratios. At a 1:1 protein-to-excipient mass ratio, trehalose is insufficient to ensure adequate protein stability after stress under high humidity, which leads to a significant change in conformational stability and the highest degree of subvisible particle formation for mAb1, primarily due to trehalose recrystallization and high-temperature stresses, while the combination of HPβCD and trehalose has resulted in improved protein stability with a reduction in aggregation propensity. These results show that a combination of HPβCD and trehalose is a viable approach in mitigating trehalose recrystallization and maintaining protein stability of mAbs in spray-dried formulations.
- 10 July 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22  (8) , 4983-4994
Combination of Hydroxypropyl-Beta-Cyclodextrin and Trehalose for Improved Stability of Spray-Dried Monoclonal Antibodies
Developing a stabilized spray-dried formulation for proteins is one key approach to extending the stability of a dehydrated drug product and providing a broad range of different drug delivery applications. Trehalose has been extensively studied as an excipient to preserve the protein stability in spray-dried formulations. However, the hygroscopic nature of amorphous trehalose makes it prone to recrystallization upon exposure to high temperature and humidity conditions, which can be detrimental to protein stability in the solid state. Herein, we report a formulation approach with the use of 2-hydroxypropyl-β-cyclodextrin (HPβCD) in combination with trehalose to enhance the physical stability of spray-dried solids by inhibiting or delaying the recrystallization of trehalose. Specifically, the effect of HPβCD and trehalose as an excipient alone or the combination of both excipients in stabilizing a model therapeutic monoclonal antibody (mAb1) in a spray-dried formulation has been evaluated at 25 °C/60% relative humidity (RH) and 40 °C/75% RH over 4 weeks. In the solid state, HPβCD can inhibit trehalose recrystallization of spray-dried solids exposed to stress conditions of higher temperatures and humidity. The recrystallization tendency of trehalose was found to be dependent on the protein-to-excipient mass ratios. At a 1:1 protein-to-excipient mass ratio, trehalose is insufficient to ensure adequate protein stability after stress under high humidity, which leads to a significant change in conformational stability and the highest degree of subvisible particle formation for mAb1, primarily due to trehalose recrystallization and high-temperature stresses, while the combination of HPβCD and trehalose has resulted in improved protein stability with a reduction in aggregation propensity. These results show that a combination of HPβCD and trehalose is a viable approach in mitigating trehalose recrystallization and maintaining protein stability of mAbs in spray-dried formulations.
- 19 March 2019
- Published by Springer Nature in Pharmaceutical Research
- Vol. 36  (5) , 1-10
Oligo(Lactic Acid)8-Rapamycin Prodrug-Loaded Poly(Ethylene Glycol)-block-Poly(Lactic Acid) Micelles for Injection
Purpose To prepare an oligo(lactic acid)8-rapamycin prodrug (o(LA)8-RAP)-loaded poly(ethylene glycol)-block-poly(lactic acid) (PEG-b-PLA) micelle for injection and characterize its compatibility and performance versus a RAP-loaded PEG-b-PLA micelle for injection in vitro and in vivo. Methods Monodisperse o(LA)8 was coupled on RAP at the C-40 via DCC/DMAP chemistry, and conversion of o(LA)8-RAP prodrug into RAP was characterized in vitro. Physicochemical properties of o(LA)8-RAP- and RAP-loaded PEG-b-PLA micelles and their antitumor efficacies in a syngeneic 4 T1 breast tumor model were compared. Results Synthesis of o(LA)8-RAP prodrug was confirmed by 1H NMR and mass spectroscopy. The o(LA)8-RAP prodrug underwent conversion in PBS and rat plasma by backbiting and esterase-mediated cleavage, respectively. O(LA)8-RAP-loaded PEG-b-PLA micelles increased water solubility of RAP equivalent to 3.3 mg/ml with no signs of precipitation. Further, o(LA)8-RAP was released more slowly than RAP from PEG-b-PLA micelles. With added physical stability, o(LA)8-RAP-loaded PEG-b-PLA micelles significantly inhibited tumor growth relative to RAP-loaded PEG-b-PLA micelles in 4 T1 breast tumor-bearing mice without signs of acute toxicity. Conclusions An o(LA)8-RAP-loaded PEG-b-PLA micelle for injection is more stable than a RAP-loaded PEG-b-PLA micelle for injection, and o(LA)8-RAP converts into RAP rapidly in rat plasma (t1/2 = 1 h), resulting in antitumor efficacy in a syngeneic 4 T1 breast tumor model.
- 19 March 2019
- Published by Springer Nature in Pharmaceutical Research
- Vol. 36  (5) , 1-10
Oligo(Lactic Acid)8-Rapamycin Prodrug-Loaded Poly(Ethylene Glycol)-block-Poly(Lactic Acid) Micelles for Injection
Purpose To prepare an oligo(lactic acid)8-rapamycin prodrug (o(LA)8-RAP)-loaded poly(ethylene glycol)-block-poly(lactic acid) (PEG-b-PLA) micelle for injection and characterize its compatibility and performance versus a RAP-loaded PEG-b-PLA micelle for injection in vitro and in vivo. Methods Monodisperse o(LA)8 was coupled on RAP at the C-40 via DCC/DMAP chemistry, and conversion of o(LA)8-RAP prodrug into RAP was characterized in vitro. Physicochemical properties of o(LA)8-RAP- and RAP-loaded PEG-b-PLA micelles and their antitumor efficacies in a syngeneic 4 T1 breast tumor model were compared. Results Synthesis of o(LA)8-RAP prodrug was confirmed by 1H NMR and mass spectroscopy. The o(LA)8-RAP prodrug underwent conversion in PBS and rat plasma by backbiting and esterase-mediated cleavage, respectively. O(LA)8-RAP-loaded PEG-b-PLA micelles increased water solubility of RAP equivalent to 3.3 mg/ml with no signs of precipitation. Further, o(LA)8-RAP was released more slowly than RAP from PEG-b-PLA micelles. With added physical stability, o(LA)8-RAP-loaded PEG-b-PLA micelles significantly inhibited tumor growth relative to RAP-loaded PEG-b-PLA micelles in 4 T1 breast tumor-bearing mice without signs of acute toxicity. Conclusions An o(LA)8-RAP-loaded PEG-b-PLA micelle for injection is more stable than a RAP-loaded PEG-b-PLA micelle for injection, and o(LA)8-RAP converts into RAP rapidly in rat plasma (t1/2 = 1 h), resulting in antitumor efficacy in a syngeneic 4 T1 breast tumor model.
- 1 March 2019
- Published by Elsevier in Journal of Controlled Release
- Vol. 298, 186-193
Poly(ethylene glycol)-block-poly(d,l-lactic acid) micelles containing oligo(lactic acid)8-paclitaxel prodrug: In Vivo conversion and antitumor efficacy
- 1 March 2019
- Published by Elsevier in Journal of Controlled Release
- Vol. 298, 186-193
Poly(ethylene glycol)-block-poly(d,l-lactic acid) micelles containing oligo(lactic acid)8-paclitaxel prodrug: In Vivo conversion and antitumor efficacy
- 29 June 2018
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 12  (7) , 7406-7414
Stereocomplex Prodrugs of Oligo(lactic acid)n-Gemcitabine in Poly(ethylene glycol)-block-poly(d,l-lactic acid) Micelles for Improved Physical Stability and Enhanced Antitumor Efficacy
Herein we demonstrate the formation of stereocomplex prodrugs of oligo(l-lactic acid)n-gemcitabine (o(LLA)n-GEM) and oligo(d-lactic acid)n-gemcitabine (o(DLA)n-GEM) for stable incorporation in poly(ethylene glycol)-block-poly(d,l-lactic acid) (PEG-b-PLA) micelles. O(LLA)n or o(DLA)n was attached at the amino group (4-(N)) of GEM via an amide linkage. When n = 10, a 1:1 mixture of o(LLA)10-GEM and o(DLA)10-GEM (o(L+DLA)10-GEM) was able to form a stereocomplex with a distinctive crystalline pattern. Degradation of o(L+DLA)10-GEM was driven by both backbiting conversion and esterase contribution, generating primarily o(L+DLA)1-GEM and GEM. O(L+DLA)10-GEM stably loaded in PEG-b-PLA micelles in the size range of 140–200 nm with an unexpected elongated morphology. The resulting micelles showed improved physical stability in aqueous media and inhibited backbiting conversion of o(L+DLA)10-GEM within micelles. Release of o(L+DLA)10-GEM from micelles was relatively slow, with a t1/2 at ca. 60 h. Furthermore, weekly administration of o(L+DLA)10-GEM micelles i.v. displayed potent antitumor activity in an A549 human non-small-cell lung carcinoma xenograft model. Thus, stereocomplexation of isotactic o(LLA)n and o(DLA)n acts as a potential prodrug strategy for improved stability and sustained drug release in PEG-b-PLA micelles.
- 29 June 2018
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 12  (7) , 7406-7414
Stereocomplex Prodrugs of Oligo(lactic acid)n-Gemcitabine in Poly(ethylene glycol)-block-poly(d,l-lactic acid) Micelles for Improved Physical Stability and Enhanced Antitumor Efficacy
Herein we demonstrate the formation of stereocomplex prodrugs of oligo(l-lactic acid)n-gemcitabine (o(LLA)n-GEM) and oligo(d-lactic acid)n-gemcitabine (o(DLA)n-GEM) for stable incorporation in poly(ethylene glycol)-block-poly(d,l-lactic acid) (PEG-b-PLA) micelles. O(LLA)n or o(DLA)n was attached at the amino group (4-(N)) of GEM via an amide linkage. When n = 10, a 1:1 mixture of o(LLA)10-GEM and o(DLA)10-GEM (o(L+DLA)10-GEM) was able to form a stereocomplex with a distinctive crystalline pattern. Degradation of o(L+DLA)10-GEM was driven by both backbiting conversion and esterase contribution, generating primarily o(L+DLA)1-GEM and GEM. O(L+DLA)10-GEM stably loaded in PEG-b-PLA micelles in the size range of 140–200 nm with an unexpected elongated morphology. The resulting micelles showed improved physical stability in aqueous media and inhibited backbiting conversion of o(L+DLA)10-GEM within micelles. Release of o(L+DLA)10-GEM from micelles was relatively slow, with a t1/2 at ca. 60 h. Furthermore, weekly administration of o(L+DLA)10-GEM micelles i.v. displayed potent antitumor activity in an A549 human non-small-cell lung carcinoma xenograft model. Thus, stereocomplexation of isotactic o(LLA)n and o(DLA)n acts as a potential prodrug strategy for improved stability and sustained drug release in PEG-b-PLA micelles.
- Open Access
- 28 March 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12  (3) , e0174658
Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer
Advanced prostate cancers that are resistant to all current therapies create a need for new therapeutic strategies. One recent innovative approach to cancer therapy is the simultaneous use of multiple FDA-approved drugs to target multiple pathways. A challenge for this approach is caused by the different solubility requirements of each individual drug, resulting in the need for a drug vehicle that is non-toxic and capable of carrying multiple water-insoluble antitumor drugs. Micelles have recently been shown to be new candidate drug solubilizers for anti cancer therapy. This study set out to examine the potential use of multi-drug loaded micelles for prostate cancer treatment in preclinical models including cell line and mouse models for prostate cancers with Pten deletions. Specifically antimitotic agent docetaxel, mTOR inhibitor rapamycin, and HSP90 inhibitor 17-N-allylamino-17-demethoxygeldanamycin were incorporated into the micelle system (DR17) and tested for antitumor efficacy. In vitro growth inhibition of prostate cancer cells was greater when all three drugs were used in combination compared to each individual drug, and packaging the drugs into micelles enhanced the cytotoxic effects. At the molecular level DR17 targeted simultaneously several molecular signaling axes important in prostate cancer including androgen receptor, mTOR, and PI3K/AKT. In a mouse genetic model of prostate cancer, DR17 treatment decreased prostate weight, which was achieved by both increasing caspase-dependent cell death and decreasing cell proliferation. Similar effects were also observed when DR17 was administered to nude mice bearing prostate cancer cells xenografts. These results suggest that combining these three cancer drugs in multi-drug loaded micelles may be a promising strategy for prostate cancer therapy.
- 28 March 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12  (3) , e0174658
Open AccessMulti-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer
Advanced prostate cancers that are resistant to all current therapies create a need for new therapeutic strategies. One recent innovative approach to cancer therapy is the simultaneous use of multiple FDA-approved drugs to target multiple pathways. A challenge for this approach is caused by the different solubility requirements of each individual drug, resulting in the need for a drug vehicle that is non-toxic and capable of carrying multiple water-insoluble antitumor drugs. Micelles have recently been shown to be new candidate drug solubilizers for anti cancer therapy. This study set out to examine the potential use of multi-drug loaded micelles for prostate cancer treatment in preclinical models including cell line and mouse models for prostate cancers with Pten deletions. Specifically antimitotic agent docetaxel, mTOR inhibitor rapamycin, and HSP90 inhibitor 17-N-allylamino-17-demethoxygeldanamycin were incorporated into the micelle system (DR17) and tested for antitumor efficacy. In vitro growth inhibition of prostate cancer cells was greater when all three drugs were used in combination compared to each individual drug, and packaging the drugs into micelles enhanced the cytotoxic effects. At the molecular level DR17 targeted simultaneously several molecular signaling axes important in prostate cancer including androgen receptor, mTOR, and PI3K/AKT. In a mouse genetic model of prostate cancer, DR17 treatment decreased prostate weight, which was achieved by both increasing caspase-dependent cell death and decreasing cell proliferation. Similar effects were also observed when DR17 was administered to nude mice bearing prostate cancer cells xenografts. These results suggest that combining these three cancer drugs in multi-drug loaded micelles may be a promising strategy for prostate cancer therapy.
- Open Access
- 11 November 2016
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 7, 1799
Membrane-Active Epithelial Keratin 6A Fragments (KAMPs) Are Unique Human Antimicrobial Peptides with a Non-αβ Structure
Antibiotic resistance is a pressing global health problem that threatens millions of lives each year. Natural antimicrobial peptides and their synthetic derivatives, including peptoids and peptidomimetics, are promising candidates as novel antibiotics. Recently, the C-terminal glycine-rich fragments of human epithelial keratin 6A were found to have bactericidal and cytoprotective activities. Here, we used an improved 2-dimensional NMR method coupled with a new protocol for structural refinement by low temperature simulated annealing to characterize the solution structure of these kerain-derived antimicrobial peptides (KAMPs). Two specific KAMPs in complex with membrane mimicking sodium dodecyl sulfate (SDS) micelles displayed amphipathic conformations with only local bends and turns, and a central 10-residue glycine-rich hydrophobic strip that is central to bactericidal activity. To our knowledge, this is the first report of non-αβ structure for human antimicrobial peptides. Direct observation of Staphylococcus aureus and Pseudomonas aeruginosa by scanning and transmission electron microscopy showed that KAMPs deformed bacterial cell envelopes and induced pore formation. Notably, in competitive binding experiments, KAMPs demonstrated binding affinities to LPS and LTA that did not correlate with their bactericidal activities, suggesting peptide-LPS and peptide-LTA interactions are less important in their mechanisms of action. Moreover, immunoprecipitation of KAMPs-bacterial factor complexes indicated that membrane surface lipoprotein SlyB and intracellular machineries NQR sodium pump and ribosomes are potential molecular targets for the peptides. Results of this study improve our understanding of the bactericidal function of epithelial cytokeratin fragments, and highlight an unexplored class of human antimicrobial peptides, which may serve as non-αβ peptide scaffolds for the design of novel peptide-based antibiotics.
- 11 November 2016
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 7, 1799
Open AccessMembrane-Active Epithelial Keratin 6A Fragments (KAMPs) Are Unique Human Antimicrobial Peptides with a Non-αβ Structure
Antibiotic resistance is a pressing global health problem that threatens millions of lives each year. Natural antimicrobial peptides and their synthetic derivatives, including peptoids and peptidomimetics, are promising candidates as novel antibiotics. Recently, the C-terminal glycine-rich fragments of human epithelial keratin 6A were found to have bactericidal and cytoprotective activities. Here, we used an improved 2-dimensional NMR method coupled with a new protocol for structural refinement by low temperature simulated annealing to characterize the solution structure of these kerain-derived antimicrobial peptides (KAMPs). Two specific KAMPs in complex with membrane mimicking sodium dodecyl sulfate (SDS) micelles displayed amphipathic conformations with only local bends and turns, and a central 10-residue glycine-rich hydrophobic strip that is central to bactericidal activity. To our knowledge, this is the first report of non-αβ structure for human antimicrobial peptides. Direct observation of Staphylococcus aureus and Pseudomonas aeruginosa by scanning and transmission electron microscopy showed that KAMPs deformed bacterial cell envelopes and induced pore formation. Notably, in competitive binding experiments, KAMPs demonstrated binding affinities to LPS and LTA that did not correlate with their bactericidal activities, suggesting peptide-LPS and peptide-LTA interactions are less important in their mechanisms of action. Moreover, immunoprecipitation of KAMPs-bacterial factor complexes indicated that membrane surface lipoprotein SlyB and intracellular machineries NQR sodium pump and ribosomes are potential molecular targets for the peptides. Results of this study improve our understanding of the bactericidal function of epithelial cytokeratin fragments, and highlight an unexplored class of human antimicrobial peptides, which may serve as non-αβ peptide scaffolds for the design of novel peptide-based antibiotics.
- 27 July 2016
- Published by Springer Nature in Frontiers of Chemical Science and Engineering
- Vol. 10  (3) , 348-359
Polymeric micelle nanocarriers in cancer research
- 27 July 2016
- Published by Springer Nature in Frontiers of Chemical Science and Engineering
- Vol. 10  (3) , 348-359
Polymeric micelle nanocarriers in cancer research